“Devastating” and “dismal.” That’s how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months. New research out of the University of Michigan supports combining two approaches to fight back against gliomas: attacking the tumor with gene therapy while...
Tag: <span>Gene Therapy</span>
Post
After one dose of gene therapy, hemophilia B patients maintain near-normal levels of clotting factor
Researchers are reporting the highest and most sustained levels to date of an essential blood-clotting factor IX in patients with the inherited bleeding disorder hemophilia B. After receiving a single dose of an experimental gene therapy in a clinical trial, patients with hemophilia produced near-normal levels of clotting factor IX, allowing them to stop clotting...